Jove
Visualize
Contact Us

Related Experiment Videos

New Drug Update 2020.

Daniel A Hussar1, Laura A Finn1

  • 1Philadelphia College of Pharmacy at the University of the Sciences, Philadelphia, Pennsylvania.

The Senior Care Pharmacist
|March 26, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Student Pharmacist State Anxiety on Vasopressor Calculation Accuracy in Advanced Cardiac Life Support Simulations.

American journal of pharmaceutical education·2024
Same author

A Tribute to Dr. Daniel A. Hussar.

The Senior care pharmacist·2021
Same author

New Drugs 2021, Part 2.

Nursing·2021
Same author

New Drugs 2021, Part 1.

Nursing·2021
Same author

New drugs 2020, part 3.

Nursing·2020
Same author

Advanced cardiac life support certification for student pharmacists improves simulated patient survival.

Currents in pharmacy teaching & learning·2020
Same journal

Can Technology Simplify Aging Care-or Just Shift the Complexity?

The Senior care pharmacist·2026
Same journal

Transitioning Medication-Related Home Visits to a Cognitively Accessible Digital Intervention in Home Care: A Practice Innovation Pilot.

The Senior care pharmacist·2026
Same journal

Perception of Technology to Support Medication Management Among Community-dwelling African American Older Adults.

The Senior care pharmacist·2026
Same journal

ASCP Policy Review Committee.

The Senior care pharmacist·2026
Same journal

Initial Evaluation of L-mMRC Severity Tool in Staging COPD in the Skilled Nursing Setting.

The Senior care pharmacist·2026
Same journal

Dispense This: How AI Is Reshaping Pharmacy's Clinical Services.

The Senior care pharmacist·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

This review evaluates five new medications for common senior health issues, including hypercholesterolemia and Parkinson's disease. Each drug is rated using the New Drug Comparison Rating (NDCR) system to assess benefits and drawbacks.

Area of Science:

  • Geriatrics
  • Pharmacology
  • Drug Development

Background:

  • Older adults frequently experience conditions such as hypercholesterolemia, Parkinson's disease, insomnia, schizophrenia, and age-related macular degeneration.
  • The pharmaceutical market continuously introduces new therapeutic agents to address these prevalent health concerns.

Purpose of the Study:

  • To review five recently marketed drugs for conditions common in the elderly population.
  • To evaluate the properties, advantages, and disadvantages of these new medications.
  • To assign a rating to each drug using the New Drug Comparison Rating (NDCR) system.

Main Methods:

  • Selection of five new drugs launched within the past year targeting geriatric conditions.
  • Detailed discussion of the uses and key characteristics of each selected drug.

Related Experiment Videos

  • Application of the New Drug Comparison Rating (NDCR) system to assess and compare the drugs.

    • Main Results:

    • The review provides an analysis of new treatments for hypercholesterolemia, Parkinson's disease, insomnia, schizophrenia, and age-related macular degeneration.
    • Each drug's profile includes identified benefits and drawbacks.
    • A comparative rating is established for each agent based on the NDCR criteria.

    Conclusions:

    • The New Drug Comparison Rating (NDCR) system offers a structured approach to evaluating new pharmaceutical agents for geriatric care.
    • This review highlights key considerations for clinicians when selecting among new treatment options for common conditions in older patients.